Several studies suggest that, together with glucose variability, the variability of other risk
factors, as blood pressure, plasma lipids, heart rate, body weight, and serum uric acid, might …

Elevated low-density lipoprotein cholesterol (LDL-C) level is associated with an increased
risk of atherosclerotic cardiovascular disease. Although high-intensity lipid-lowering …

Background In a previous study, a single injection of inclisiran, a chemically synthesized
small interfering RNA designed to target PCSK9 messenger RNA, was found to produce …

Background: Variability in metabolic parameters, such as fasting blood glucose and
cholesterol concentrations, blood pressure, and body weight can affect health outcomes. We …

Importance Sustained reductions in low-density lipoprotein cholesterol (LDL-C) with lipid-
lowering therapies that require frequent dosing are reliant on patient adherence, and poor …

Inclisiran is a novel drug that inhibits PCSK9 synthesis specifically in the liver, harnessing
the natural mechanism of RNAi. Phase I and II data show that inclisiran lowers low-density …

Until recently, intraindividual visit-to-visit variability of cardiovascular risk factors has been
dismissed as random fluctuation. This simplistic concept was challenged by demonstrating …

Background While high levels of lipids and lipid variability are established risk factors for
atherosclerotic cardiovascular disease, their roles in the development of atrial fibrillation …

Context The bidirectional relationship between low high-density lipoprotein cholesterol
(HDL-C) and glucose intolerance is well established. Recent studies suggested an …

Aim To examine the associations between variability in lipids and the risk of cardiovascular
disease (CVD) and mortality in patients with type 2 diabetes based on low‐density …